Navigation Links
Blood sugar control does not help infants and children undergoing heart surgery
Date:9/7/2012

Tight blood sugar control in infants and children undergoing heart surgery does not lower the risk of infection or improve recovery, according to a study funded by the National Institutes of Health.

Infants and children who have undergone heart surgery commonly develop high blood sugar levels, which may be associated with health issues and death. Although the results of clinical trials have been mixed, some studies of adult intensive care unit (ICU) patients have found that controlling blood sugar levels with insulin resulted in fewer infections and shorter hospital stays than leaving high blood sugar levels untreated.

The Safe Pediatric Euglycemia in Cardiac Surgery (SPECS) study compared tight glycemic (blood sugar) control to standard blood sugar management in 980 children who underwent open heart surgery with heart-lung bypass. Tight glycemic control involves regularly monitoring insulin infusions to maintain normal blood sugar levels.

Compared to standard care, tight glycemic control did not reduce health care-related infections, such as pneumonia or infections of the bloodstream, urinary tract, or surgical site. Nor did it reduce the length of stay in the cardiac ICU, organ failure, or death.

The findings will be published online Sept. 7 in the New England Journal of Medicine and will appear in the print issue on Sept. 27.

"Children have often had to accept medicines and treatments based on what is known to work in adults, but treatments that benefit adults do not necessarily benefit children," said Michael Lauer, M.D., director of the Division of Cardiovascular Sciences in the NIH's National Heart, Lung, and Blood Institute (NHLBI), which supported the study. "This study underscores the importance of pediatric clinical research."

During the SPECS study, which was conducted at the Harvard Medical School, Boston Children's Hospital, and the University of Michigan C.S. Mott Children's Hospital in Ann Arbor, participants from birth to 36 months old were randomly assigned to either a tight glycemic control group or a standard ICU care group and followed for up to 30 days. The tight glycemic control group received insulin to maintain normal blood sugar levels, while the standard care group did not receive insulin. Both groups underwent continuous monitoring for hypoglycemia, or low blood sugar. Participants in the tight glycemic control group quickly (in about six hours) achieved normal blood sugar levels with few cases of severe hypoglycemia.

"Our protocol achieved tight and effective glycemic control, but that did not improve the children's health outcomes," said Michael Agus, M.D., at Boston Children's Hospital and the study's principal investigator. "Further studies may still show that this therapy benefits a different patient population."

Dr. Agus is following up with a subset of the study participants as they turn 1 year old and as they turn 3 years old to find out whether actively managing blood sugar levels after surgery has any long-term effects.


'/>"/>

Contact: NHLBI Communications Office
nhlbi_news@nhlbi.nih.gov
301-496-4236
NIH/National Heart, Lung and Blood Institute
Source:Eurekalert

Related medicine news :

1. Infection Might Raise Blood Clot Risk for Older Adults: Study
2. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
3. Common Blood Pressure Drug Safe for Heart Failure: Study
4. Certain Birth Control Pills May Carry Higher Blood Clot Risk: FDA
5. High Blood Pressure May Be Especially Lethal for Blacks
6. Changes in gene expression may help explain high blood pressure in pregnancy
7. Researchers Develop Blood Test for Depression
8. Naturopathic care can improve blood sugar, mood in diabetes
9. Diabetes Groups Issue New Guidelines on Blood Sugar
10. Exercise May Help Patients With High Blood Pressure Live Longer
11. Additional blood pressure screening may reduce incidence of CVD events and death by up to 3 percent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2017)... ... ... The quest to develop a cure for HIV has long been plagued by ... has a knack for lying dormant in immune cells at levels undetectable to all ... Graduate School of Public Health announced today in Nature Medicine that they’ve created a ...
(Date:5/28/2017)... Melbourne, FL (PRWEB) , ... May 28, 2017 ... ... Partners of America (PPOA), is proud to announce that Jorge Fernandez-Silva, M.D., has ... comprehensive interventional pain management, a specialty that concentrates on minimally invasive techniques to ...
(Date:5/27/2017)... ... May 26, 2017 , ... A May 8 article ... for colds or respiratory issues that are not responsive to antibiotics nevertheless obtain prescriptions ... may be largely responsible for the problem both in Canada and the United States. ...
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare professionals ... event was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. ... network of independent hearing healthcare providers to help them stay ahead in the industry. ...
(Date:5/26/2017)... ... May 26, 2017 , ... The American Parkinson Disease Association’s ... eighty-nine grant submissions all vying for nearly $1,000,000 in funding that will be ... The American Parkinson Disease Association (APDA) is focused on advancing scientific research that ...
Breaking Medicine News(10 mins):
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, ... innovative medical devices for pressure ulcer prevention, will ... American Association of Critical Care Nurses, National Teaching ... 22-25. The Leaf Patient Monitoring System ... for the hospital environment.  The system seamlessly tracks ...
(Date:5/18/2017)... 18, 2017  Two Bayer U.S. Pharmaceutical leaders received ... its recent 28 th Woman of the ... showcases HBA,s longstanding mission of furthering the advancement and ... Cindy Powell-Steffen , senior director of brand ... and Libby Howe , a regional business manager ...
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
Breaking Medicine Technology: